Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vaginal Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 80Carboplatin 73Paclitaxel 58Cisplatin 58Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 37Dexamethasone 37Oxaliplatin 34Fluorouracil 33Bevacizumab 33Pemetrexed 32Leucovorin 32Doxorubicin 32Cyclophosphamide 31durvalumab 29Radiotherapy 29Radiation 28Capecitabine 28Rituximab 25Letrozole 25Etoposide 24Nivolumab 23Irinotecan 23Vincristine 22Taxes 21Lenalidomide 21Prednisone 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT02466971 2026-05-29

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI)

Phase 3 Active not recruiting
450 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡